Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer

---

Uysal M., OZDOGAN M., KARGI A., GUNDUZ S., GOKSU S. S., TATLI A. M., ...More

JOURNAL OF BUON, vol.19, no.4, pp.980-984, 2014 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 19 Issue: 4
• Publication Date: 2014
• Journal Name: JOURNAL OF BUON
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.980-984
• Keywords: cyclophosphamide, etoposide, maintenance therapy, metronomic oral therapy, ovarian cancer, RANDOMIZED PHASE-III, PLATINUM-RESISTANT, INTERGROUP TRIAL, THERAPY, CARCINOMA, PACLITAXEL, CHEMOTHERAPY, CARBOPLATIN, TOPOTECAN, WOMEN
• Akdeniz University Affiliated: Yes

Abstract

Purpose: In ovarian cancer permanent remission may be provided with optimal cytoreductive surgery and adjuvant chemotherapy. However survival is short in patients with residual macroscopic disease after surgery or recurrent ovarian cancer. Applicable maintenance therapies with low toxicity are required to prolong progression-free survival (PFS) for patients with no curative treatment options. In this study, we investigated the effect of maintenance metronomic oral cyclophosphamide and etoposide (CE) in ovarian cancer patients with post operative residual or recurrent disease.